Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 8.30 8.20 8.40 8.30 8.30 8.30 25,000 08:00:14
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.2 -2.1 - 23

Evgen Pharma PLC Update on patient recruitment

17/02/2021 7:00am

UK Regulatory (RNS & others)

Evgen Pharma (LSE:EVG)
Historical Stock Chart

From Feb 2021 to Apr 2021

Click Here for more Evgen Pharma Charts.


RNS Number : 3128P

Evgen Pharma PLC

17 February 2021

Evgen Pharma plc

("Evgen" or the "Company")

Update on patient recruitment

STAR COVID-19 trial exceeds 100 patients

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, announces that as of 16 February, a total of 102 patients had been recruited and randomised to the STAR trial ("SFX-01 Treatment for Acute Respiratory infections").

This Phase II/III trial is a randomised, placebo-controlled trial, sponsored by the University of Dundee and funded by the UK charity LifeArc. It is investigating whether the Company's lead asset, SFX-01, can reduce the severity, or prevent the onset of, acute respiratory distress syndrome ("ARDS") in patients with suspected COVID-19. Patients may be included in the study if they are infected with SARS-CoV-2 or another respiratory infections causing community-acquired pneumonia.

The trial design includes an assessment of safety and futility by a Data Safety and Monitoring Board ("DSMB") who will review unblinded data on the first 100 patients treated. In addition to the DSMB safety and futility assessment, Dundee University ("the Sponsor") has decided to review the top-level unblinded data in a preliminary assessment of possible efficacy. This may lead to adjustments to the design of the trial for remaining patients, including in patient numbers, and possibly early termination for either safety, futility or alternatively, strong efficacy. It is expected that this initial data will be available during the second quarter of calendar 2021.

The Sponsor has also requested that the DSMB review data from the first 60 patients solely for safety and this process will be starting shortly. The outcome of this is expected to be available in early Q2 2021.

Completion of recruitment to the STAR trial is anticipated at the end of 2021/Q1 2022, assuming there are no substantial changes in the total patients to be recruited.

Dr Huw Jones, CEO of Evgen, commented : "We are pleased with the recruitment progress in this trial and would again like to thank Professor James Chalmers and his colleagues at Dundee for their considerable efforts in a very challenging clinical environment. Randomising over 100 patients is an important milestone in this trial and takes us a step closer to receiving the initial data from the study. We look forward to further updating the market as we progress through this important trial."

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.


 Evgen Pharma plc                                         via Walbrook 
 Barry Clare, Chairman 
  Dr Huw Jones, CEO 
 Richard Moulson, CFO 
 finnCap                                         +44 (0)20 7220 0500 
 Geoff Nash / Teddy Whiley (Corporate 
 Alice Lane (ECM) 
 Walbrook PR                              +44 (0)20 7933 878 or 
                                                   +44 (0)7980 541 893 / +44 (0)7876 
 Paul McManus / Anna Dunphy                                                  741 001 

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.

The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

For further information, please visit:

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

February 17, 2021 02:00 ET (07:00 GMT)

1 Year Evgen Pharma Chart

1 Year Evgen Pharma Chart

1 Month Evgen Pharma Chart

1 Month Evgen Pharma Chart
ADVFN Advertorial
Your Recent History
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210413 07:50:57